Medexus Pharmaceuticals Inc.
MEDXF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -4.2% | 4.6% | 40.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 52.2% | 52.6% | 55.5% | 49.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | -$0 |
| % Margin | 7.6% | 9.5% | 7% | -19.6% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | $0 | $0 | -$0 | -$0 |
| Tax Expense | -$0 | $0 | -$0 | -$0 |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 2.1% | -0.2% | 1.1% | -3.8% |
| EPS | 0.084 | -0.01 | 0.06 | -0.15 |
| % Growth | 985.3% | -115.8% | 140% | – |
| EPS Diluted | 0.082 | -0.01 | 0.06 | -0.14 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 15.5% | 17.1% | 13.5% | 19.8% |